I n 1948, Gilje reported that venous ulcers covered with adhesive tape healed faster than those covered by gauze dressings. 1 This may be the first published controlled clinical trial suggesting that maintaining tissue hydration in a fresh wound might lead to a better healing result (ie, moist wound healing). Since the early 1960s, there has been a steadily growing interest in wound healing and new approaches for treatment. It is fair to credit George Winter's studies showing the positive effects of occlusive film dressings on epithelization in porcine skin wounds as an early impetus for attention to this subject. 2,3 Following Winter's publications showing enhanced epithelization in occluded animal wounds, others soon confirmed and reported the relevance of his findings to experimental human skin wounds. 4, 5 Today most workers recognize the clinical applications and value of moist wound healing even though this approach is not used universally.
Other research that promoted interest in wound healing included Cohen's discovery and elucidation of epidermal growth factor, a polypeptide that was suspected to have therapeutic potential for improving the healing of wounds. 6, 7 New approaches in cell biology leading to the production of human proteins through recombinant technologies further advanced the idea and availability of growth factors as possible therapeutic agents. Although the list of factors studied has grown, only platelet-derived growth factor has been shown to be effective in clinical trials and been approved for clinical use by regulatory agencies. 8, 9 This is not to say that other growth factors or combinations are ineffective, but rather that there have not yet been successful developments and clinical trials that have undergone regulatory scrutiny. The techniques for identifying and producing growth factors have outpaced our understanding of the physiology of these factors in acute and chronic wounds, but over the last decade, there has been a greater focus to increase knowledge about their role. 10, 11 For growth factors to achieve the promise of improving wound healing, there are still questions that must be addressed: (1) which factors; (2) when, where, and how to deliver them; and (3) in what quantities.
In the 1980s, research into skin substitutes led to the use of in vitro produced, autologous epithelial sheets for resurfacing burn wounds 12 and the use of collagen scaffolds 13 to provide for a neodermis in third-degree burns. Later, following those advancements, living skin substitutes were developed. A bilayered skin product for the treatment of diabetic and venous ulcers 14, 15 and a dermal product for the treatment of diabetic ulcers 16 were approved by the U.S. Food and Drug Administration. Active research continues in university and industrial laboratories for the development and use of scaffolds for wounds and tissue replacement. Most of the reports on the living skin substitutes suggest that they act not as skin grafts, but rather as biological dressings that also produce an array of growth factors influencing healing. These developments were the first to emerge from the recently named field of tissue engineering.
Most of the teachings on wound healing have come from experimental studies of acute wounds in animal or human subjects. Chronic ulcers, on the other hand, do not behave in the same way as acute wounds. They are characterized as slow or nonhealing, having an ongoing underlying cause, prolonged inflammation, a bacterial burden, and an imbalance of proteinases and inhibitors. 10 With increasing knowledge, there has developed an appreciation of the unique challenges in treating chronic wounds in patients. Removing the barriers to healing in the chronic wound has led to the concept of wound bed preparation, a new way of thinking about treating the wound. [17] [18] [19] [20] With good preparation, the goal is to optimize the use of treatments and allow healing to occur normally. 17 Historically, one approach to prepare the chronic wound bed has been debridement. Simplistically, we consider debridement of the chronic wound important in removing necrotic tissue. Falanga has broadened the term to necrotic burden, which includes necrotic tissue, excess exudates, and high levels of bacteria within the dead tissue. 19 Recent studies suggest that debridement may also be important in removing senescent cells in the chronic wound, which are less competent for repair. It also removes bacteria and toxins that may impair healing. There are clear barriers to healing in the milieu of chronic wounds that are not present in acute wounds.
Attention to wound care is especially important in view of the growing aged population along with its increase in chronic wound-related problems. Progress in understanding the biology is leading to many changes in how we study wound healing and develop clinical care in today's environment. What are these changes? In brief, they include advancing biological research, developed wound care centers and the concept of multidisciplinary teams delivering care, evidencebased assessments of treatment, improved early predictors of poorly healing wounds, emphasis on prevention of ulcers, attention to cost-effectiveness of treatments, recognition of the need for outcomes research, and a move to randomized controlled trials for emerging active products. As a backdrop to this list, we see many fine new journals focused entirely on wound healing, and there is a multitude of scientific/clinical meetings each year to present and discuss progress. The ongoing renaissance of interest in wound healing augurs well for continued and future improvements in understanding and treating wounds.
